Physician profile
Nay Htyte
NPI 1639308299
$8,008.54
in general payments reported to CMS, 2019-2025
29 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,433 · 2020: $80.62 · 2021: $626 · 2022: $2,577 · 2023: $1,268 · 2024: $301 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910 · Travel and Lodging: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.92 |
| Travel and Lodging | $381.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $4,389.71 | 2019-2025 | Bioflo |
| Medtronic, INC. | $825.60 | 2022-2025 | Turbohawk, Cg Future, Hawkone |
| Tactile Systems Technology INC | $354.00 | 2022-2024 | Flexitouch Plus, Entre Plus |
| Abbott Laboratories | $322.54 | 2019-2023 | Mitraclip |
| Amgen INC. | $255.21 | 2021-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $190.35 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.14 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $171.05 | 2021-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $161.92 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $148.05 | 2021-2025 | |
| Inari Medical, INC. | $146.60 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $145.74 | 2021-2025 | Lifevest |
| Pfizer INC. | $109.80 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $98.05 | 2023-2025 | Onpattro, Amvuttra |
| Merck Sharp & Dohme LLC | $66.50 | 2022-2023 | Verquvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $51.78 | 2024 | Arcalyst |
| Boston Scientific Corporation | $47.29 | 2020 | |
| Esperion Therapeutics, INC. | $45.10 | 2021-2025 | Nexletol |
| Edwards Lifesciences Corporation | $42.67 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $39.35 | 2024-2025 | Opsumit |
| Scpharmaceuticals INC. | $36.18 | 2023-2025 | |
| Advanced Oxygen Therapy INC. | $33.33 | 2020 | |
| Glaxosmithkline, LLC. | $23.64 | 2025 | Shingrix |
| Heartflow, INC. | $23.51 | 2025 | |
| Abiomed | $22.43 | 2025 | |
| Vifor Pharma, INC. | $21.36 | 2021 | |
| Astellas Pharma US INC | $17.41 | 2021 | |
| Chiesi USA, INC. | $16.21 | 2025 | Kengreal |
| Coala Life INC | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nay Htyte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.